This list is an analysis based on recent market events. It's not an investment recommendation.
About
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headquartered in Malmö, Sweden.
The current price of ACE.ST is SEK2.97 SEK — it has increased by +2.77% in the past 24 hours. Watch Ascelia Pharma AB stock price performance more closely on the chart.
What is Ascelia Pharma AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ascelia Pharma AB stocks are traded under the ticker ACE.ST.
Is Ascelia Pharma AB stock price growing?▼
ACE.ST stock has risen by +0% compared to the previous week, the month change is a -4.31% fall, over the last year Ascelia Pharma AB has showed a +7.53% increase.
When is the next Ascelia Pharma AB earnings date?▼
Ascelia Pharma AB is going to release the next earnings report on May 14, 2026.
What is Ascelia Pharma AB revenue for the last year?▼
Ascelia Pharma AB revenue for the last year amounts to 0 SEK.
What is Ascelia Pharma AB net income for the last year?▼
ACE.ST net income for the last year is -80.03M SEK.
How many employees does Ascelia Pharma AB have?▼
As of April 01, 2026, the company has 11 employees.
In which sector is Ascelia Pharma AB located?▼
Ascelia Pharma AB operates in the Health Care sector.
When did Ascelia Pharma AB complete a stock split?▼
Ascelia Pharma AB has not had any recent stock splits.